About Gap junction alpha-5 protein
Gap junction alpha-5 protein (GJA5) is a protein
from Homo sapiens identified by UniProt accession
P36382, 358 residues long.
MolForge cross-references it against 0 known binders and
420 disease associations.
Target properties
| Protein name | Gap junction alpha-5 protein |
|---|
| UniProt accession | P36382 |
|---|
| Gene | GJA5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 358 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (420)
Diseases linked to this target (Open Targets).
- familial atrial fibrillation · score 0.62
- Atrial stand still · score 0.56
- atrial fibrillation · score 0.48
- hemoglobin measurement · score 0.43
- hematocrit · score 0.42
- erythrocyte count · score 0.41
- red blood cell density measurement · score 0.36
- PR interval · score 0.34
- mean corpuscular hemoglobin concentration · score 0.29
- left ventricular structural measurement · score 0.29
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P36382-F1 | alphafold | PREDICTED | 69.71 | — |
Amino-acid sequence (358 residues)
MGDWSFLGNF LEEVHKHSTV VGKVWLTVLF IFRMLVLGTA AESSWGDEQA DFRCDTIQPG CQNVCYDQAF PISHIRYWVL QIIFVSTPSL VYMGHAMHTV RMQEKRKLRE AERAKEVRGS GSYEYPVAEK AELSCWEEGN GRIALQGTLL NTYVCSILIR TTMEVGFIVG QYFIYGIFLT TLHVCRRSPC PHPVNCYVSR PTEKNVFIVF MLAVAALSLL LSLAELYHLG WKKIRQRFVK PRQHMAKCQL SGPSVGIVQS CTPPPDFNQC LENGPGGKFF NPFSNNMASQ QNTDNLVTEQ VRGQEQTPGE GFIQVRYGQK PEVPNGVSPG HRLPHGYHSD KRRLSKASSK ARSDDLSV
Explore Gap junction alpha-5 protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets